Alumis is debuting in an initial public offering Friday on the Nasdaq, though the $250 million IPO is less than its initial ...

AbbVie on Thursday announced it has acquired Celsius Therapeutics to expand its immunology portfolio with a first-in-class ...

Expansion across its network will mean hundreds of new employees in Cincinnati, increased ability to get complex medicines to ...

The Institute for Clinical and Economic Review has again flagged “substantial concerns” with Lykos Therapeutics’ data for its ...

Following the recently completed spinoff of cancer detection company Grail, sequencing giant Illumina said Thursday it ...

The FDA on Thursday rejected Merck and Daiichi Sankyo’s antibody-drug conjugate patritumab deruxtecan in a Complete Response ...

One patient died of respiratory failure in a Phase I study of Lyell Immunopharma’s investigational CAR-T therapy. The company ...

Novo Nordisk on Wednesday announced it is stopping a late-stage study after its candidate ocedurenone, which the pharma ...

Data showed that Eli Lilly’s Zepbound could resolve obstructive sleep apnea in at least 43% of patients, solidifying the ...

Altimmune’s obesity candidate pemvidutide strongly preserved lean muscle mass, with fat accounting for more than 78% of ...

The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going ...

After being spun off of sequencing giant Illumina, Grail on Tuesday is set to start trading on the Nasdaq Global Select ...